Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
According to World Health Organization researchers there is a rise in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug. The rise in such cases involving the pandemic 2009 A (H1N1) flu strain, also known as swine flu, took place during Australia's most recent winter: May through August of 2011.
CEL-SCI Corporation is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection) to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.
CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2011.
BBC News Magazine examines an antiviral drug called Draco, developed by Todd Rider, a research scientist at the Massachusetts Institute of Technology, "which has proven successful against all 15 viruses to which it has been applied in lab trials with human tissue and mice," including "the common cold, H1N1 or swine flu, a polio virus, dengue fever, and the notorious and fatal Ebola virus."
The flying fox is an adorable doe-eyed bat with a dark side - it is the perfect vector for emerging infectious diseases from Asia. Susan Tsang, a PhD student in ecology and evolutionary biology at The City College of New York and the CUNY Graduate Center, turned to a revolutionary way to help fund her research into how this species spreads disease.
A six year old boy’s parents have claimed that he developed narcolepsy after a swine flu vaccination. Caroline Hadfield said son Josh lost muscle control and started sleeping up to 19 hours a day three weeks after being given Pandemrix nearly two years ago.
"A group of health organizations [on Wednesday] launched a new international consortium to better prepare the clinical research community to respond to the next pandemic or other emerging health threat," CIDRAP News reports (Schnirring, 12/7).
An international consortium aimed at ensuring that the clinical research community is better prepared for the next influenza pandemic or other rapidly emerging public health threat is launched today by leading funders of medical research from across the globe.
The researchers studied the immune response of 107 pregnant women after they were injected with a single dose of non-adjuvant H1N1 vaccine. They concluded that the influenza shot boosted the immune response in pregnant women and at the same time protected neuronatal babies via the antibodies that transferred through the placenta.
Social determinants, including the lack of paid sick leave, contributed to higher risk of exposure to the influenza A (H1N1) virus among Hispanics in the U.S. during the 2009 H1N1 pandemic, according to a study led by Sandra Crouse Quinn, professor of family science and senior associate director of the Maryland Center for Health Equity at the University of Maryland School of Public Health.
NanoViricides, Inc. announced today that it has submitted a pre-IND Meeting Request to the US FDA. The Company has requested an initial meeting with the US FDA to review the Company's proposed strategy and plan for conducting safety/toxicology studies and human clinical trials required for approval of its anti-influenza clinical drug candidate, FluCide™ (i.e. NV-INF-1).
Inadequate use of masks or respirators put health care workers at risk of 2009 H1N1 infection during the earliest stages of the 2009 pandemic in the U.S., according to a study published in the December issue of Infection Control and Hospital Epidemiology, the journal of the Society of Healthcare Epidemiology of America.
A team of researchers from the Johns Hopkins Children's Center, Vanderbilt University and elsewhere have demonstrated that high blood pressure and anemia together put children with sickle cell disease (SCD) at serious danger for symptomless or so-called "silent" strokes, although either condition alone also signaled high risk.
The National Institutes of Health (NIH) has awarded $3.2 million to a team of preeminent engineering, chemistry, and biology researchers to develop a highly efficient system of generating nucleic acid molecules, called aptamers.
According to the Centers for Disease Control and Prevention (CDC), three cases of a new flu virus have been confirmed. These originated in pigs but apparently spread from person to person, in three Iowa children.
Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines.
A hand and respiratory hygiene program including frequent use of alcohol-based hand sanitizer helps reduce illness caused by influenza A and missed school days in elementary school children, reports a study in the November issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter financial results for the period ended September 30, 2011.
A natural lipid in the fluid lining the lungs inhibits influenza infections in both cell cultures and mouse models, according to researchers at National Jewish Health. These findings, combined with previous studies demonstrating effectiveness against respiratory syncytial virus, suggest that the molecule, known as POPG, may have broad antiviral activity.
SEEK, a leading UK privately-owned drug-discovery group, today announced encouraging results following the successful completion of its Universal Flu Vaccine Phase II challenge study.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.